8-K: Bio-Techne Reports Strong Q3 Fiscal 2025 Results, Announces Dividend and $500 Million Share Repurchase Program

Bio-Techne Corporation announces Q3 FY2025 results with a 6% organic revenue increase and a new $500 million share repurchase program.

Summary

• Bio-Techne Corporation reported its financial results for the third quarter ending March 31, 2025.
• Third quarter organic revenue increased by 6% to $316.2 million.
• GAAP earnings per share (EPS) was $0.14, compared to $0.31 one year ago.
• Adjusted EPS was $0.56, compared to $0.48 one year ago.
• The Protein Sciences segment saw a 7% organic growth.
• Adjusted operating margin improved to 34.9% from 33.0% in the prior year.
• The Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended March 31, 2025.
• A new share repurchase program authorizing the repurchase of up to $500 million of common stock was approved.

Sentiment

Score: 7

Explanation: The sentiment is positive due to strong organic revenue growth, improved adjusted EPS and operating margin, and the announcement of a dividend and share repurchase program. However, the decrease in GAAP EPS and operating income tempers the overall sentiment.

Positives

• Organic revenue increased by 6% in Q3 FY2025.
• Adjusted EPS increased to $0.56 from $0.48 year-over-year.
• Adjusted operating margin improved to 34.9%.
• The Protein Sciences segment showed strong growth with a 7% increase in organic revenue.
• The company announced a new share repurchase program authorizing the repurchase of up to $500 million of common stock.
• A quarterly dividend of $0.08 per share was declared, providing value to shareholders.

Negatives

• GAAP EPS decreased to $0.14 from $0.31 in the same quarter last year.
• GAAP operating income decreased 42% to $38.7 million, compared to $67.0 million in the third quarter of fiscal 2024.
• GAAP operating margin was 12.2%, compared to 22.1% in the third quarter of fiscal 2024, unfavorably impacted by a non-recurring arbitration award.

Risks

• The company acknowledges a dynamic macroenvironment.
• Forward-looking statements are subject to risks and uncertainties, including the effect of new branding and marketing initiatives, integration of new businesses and leadership, and general economic conditions.
• Currency exchange rate fluctuations could impact future results.
• The share repurchase program may be suspended, amended, or discontinued at any time.

Future Outlook

The company remains well-positioned geographically and by end market and expects to successfully navigate the current operating environment. Future cash dividends will be considered by the Board of Directors on a quarterly basis. The timing and number of shares to be repurchased will depend on factors such as the share price, economic and market conditions, and corporate and regulatory requirements.

Management Comments

• Kim Kelderman, President and Chief Executive Officer of Bio-Techne, stated that the team delivered strong third quarter results despite a dynamic macroenvironment.
• Kelderman noted improved pharma end market conditions and strong commercial execution in Protein Sciences.
• Kelderman added that the company's focus on profitability resulted in a 34.9% adjusted operating margin.

Industry Context

Bio-Techne's performance reflects the broader trends in the life sciences industry, with improving conditions in the pharma end market driving growth. The company's focus on specialized proteins and protein analysis positions it well within the biopharma and academic research communities.

Comparison to Industry Standards

• Comparing Bio-Techne to companies like Danaher or Thermo Fisher Scientific, its organic revenue growth of 6% is competitive.
• Bio-Techne's adjusted operating margin of 34.9% is strong, indicating efficient operations and profitability initiatives.
• The $500 million share repurchase program is a significant capital allocation decision, similar to those seen in other large-cap life science companies.

Stakeholder Impact

• Shareholders will benefit from the dividend payment and the potential increase in share value from the repurchase program.
• Employees may see increased job security and potential for bonuses due to the company's strong performance.
• Customers will continue to have access to innovative tools and bioactive reagents.
• The company's financial stability strengthens its relationships with suppliers and creditors.

Next Steps

• The company will host an earnings conference call on May 7, 2025.
• The Board of Directors will consider future cash dividends on a quarterly basis.
• The company will execute the $500 million share repurchase program based on market conditions and regulatory requirements.

Key Dates

Keywords

Bio-Techne, financial results, organic revenue, adjusted EPS, operating margin, Protein Sciences, dividend, share repurchase, diagnostics, spatial biology